Quantum BioPharma: Formerly FSD Pharma (Nasdaq:HUGE) – Morningstar
Quantum BioPharma, previously known as FSD Pharma, is reaching out to shareholders to join forces in a legal battle against CIBC, RBC, and others. The company has filed a lawsuit totaling over US$700M for alleged stock price manipulation. Quantum BioPharma, along with its shareholders, aims to seek justice and recover from financial losses due to this alleged illicit activity carried out by the Defendants.
To support this cause, Quantum BioPharma has assembled a team of legal experts who will pursue the recovery of losses on a contingency basis. This means that the company will not incur any legal costs throughout this process. The lawsuit seeks compensation for damages exceeding US$700M, reflecting the losses suffered by Quantum BioPharma.
The company, previously traded under the symbol HUGE, urges affected shareholders to come forward and share details of their losses. By uniting shareholders who have been impacted, Quantum BioPharma aims to strengthen its case against the alleged wrongdoers and secure justice for all affected parties.
If you have experienced losses due to shares sold during the Relevant Period, Quantum BioPharma encourages you to provide details such as your name, address, share transactions, and the impact of these losses on you and your family. By participating in this initiative, shareholders can help in the pursuit of justice. To share your information or seek further details, you can contact the company via email or phone.
Furthermore, Quantum BioPharma will provide updates on the progress of this case through its website. By visiting the Quantum vs Banks page, shareholders can access the latest information on the lawsuit and stay informed about important developments.
In addition to this legal battle, Quantum BioPharma is a biopharmaceutical company dedicated to developing innovative solutions for neurodegenerative and metabolic disorders, among others. Through its subsidiary, Lucid Psycheceuticals Inc., the company is focused on research and development in this important field.
As the legal proceedings unfold, Quantum BioPharma remains committed to its mission of advancing biotech solutions and seeking justice for shareholders affected by alleged stock price manipulation. Shareholders are encouraged to engage with the company and stay informed about this critical initiative.
